Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 51 record(s)

Req # A-2023-000313

The licensed indications for use for MicroTheurapeutic‘s Axium Embolization Coils on Medical Device License 63475 that Health Canada has on file for this license.

Organization: Health Canada

160 page(s)
September 2023

Req # A-2023-000713

A copy of all information released as part of Freedom of Information (FOI) request number A-2016-00717, completed by your office around October 1, 2016.

Organization: Health Canada

4 page(s)
September 2023

Req # A-2021-000663

Adverse Drug Reaction (ADR) for HYOSCINE BUTYLBROMIDE. Report number: E2B_03293753.

Organization: Health Canada

14 page(s)
September 2023

Req # A-2022-001661

Adverse Drug Reaction (ADR). Report number: E2B_05716216.

Organization: Health Canada

11 page(s)
September 2023

Req # A-2023-000352

Adverse Drug Reaction (ADR) for LANREOTIDE. Report number: E2B_05322380.

Organization: Health Canada

23 page(s)
September 2023

Req # A-2023-000381

Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_03009425, E2B_01335934, E2B_02096585, E2B_01892634, E2B_02393844, E2B_02387551, E2B_02826826, E2B_02867073, E2B_02455143, E2B_03044908.

Organization: Health Canada

258 page(s)
September 2023

Req # A-2023-000416

Adverse Drug Reaction (ADR). Report number: 000630138.

Organization: Health Canada

3 page(s)
September 2023

Req # A-2023-000468

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-103496-815, Investing in Canada Plan.

Organization: Health Canada

20 page(s)
September 2023

Req # A-2023-000529

Adverse Drug Reaction (ADR). Report number: E2B_02891245.

Organization: Health Canada

28 page(s)
September 2023

Req # A-2023-000548

Adverse Drug Reaction (ADR). Report number: E2B_06076856.

Organization: Health Canada

69 page(s)
September 2023
Date modified: